Sign in
4

Changes in Ownership

Travere Therapeutics, Inc. Filed Acc 0001415889-25-002003

Director sold 16,000 shares at $20.00 ($320,000)

  • Director acquired 16,000 shares (option exercise)
  • Traded under a Rule 10b5-1 plan

From the SEC's structured data for this filing

Trades in this filing

Table I: Non-derivative

Insider Date Transaction Shares Price Value Owned after D/I
Baynes Roy D. Director 2025-01-23 Option exercise 10b5-1 +16,000 $17.50 $280,000 47,000 D: show line 1 in the form
Baynes Roy D. Director 2025-01-23 Sale 10b5-1 −16,000 $20.00 $320,000 31,000 D: show line 2 in the form
Open-market sales · 16,000 sh · avg $20.00 · $320,000

Table II: Derivative

Insider Date Transaction Shares Price Value Exercise Expires Underlying Owned after D/I
Baynes Roy D. Director 2025-01-23 Option exercise · Stock option (right to buy) 10b5-1 −16,000 0 D: show line 3 in the form
Loading xslF345X05/form4-01242025_010152.xml…